March 6, 2026
Two Johnson & Johnson units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were overcharged for the pulmonary hypertension drug Tracleer.
The plaintiffs, including the Government Employees Health Association and other entities that paid or provided reimbursement for their members’ use of Tracleer, alleged in their lawsuit that the drugmakers delayed competition for a generic version of the medication.
Sharon Robertson, a lead attorney for the plaintiffs, said the settlement will provide “meaningful relief” for the class of so-called third-party payors that purchased Tracleer and its generic version over the span of nearly a decade.
The settlement covers Tracleer purchases in 31 states, the District of Columbia and Puerto Rico between December 2015 and September 2024.
For plaintiffs: Sharon Robertson of Cohen Milstein Sellers & Toll; and Thomas Sobol of Hagens Berman Sobol Shapiro
Read Johnson & Johnson Units to Pay $65 Million to Settle Tracleer Antitrust Class Action.